2023 Drug approvals for FDA and EMA; oncology continues strongly in pole position

2023 Drug approvals for FDA and EMA; oncology continues strongly in pole position

Whilst appropriate focus has been on the US FDA approving 55 new drugs for 2023, of which 20 are first-in-class, let’s not forget that in Europe, great progress also occurred with the European Medicine Agency (EMA) approving 77 new drugs in 2023, of which 39 are the equivalent of first-in-class. The role of these regulatory agencies is to expedite new, innovative and clinically meaningful drugs to deserving patients. For both the FDA and EMA 2023 drug approvals, oncology drugs took pole position: there were 16 new oncology indications (29% of the total) for the FDA and 25 new oncology indications (32% of the total) for EMA.  Oncology drugs continue to be at the forefront for both clinical and market development.

READ THE ARTICLE – https://www.ema.europa.eu/en/documents/other/human-medicines-highlights-2023_en.pdf

 

 

Share this post